MedTrace Logo

Cerebral Perfusion Pressure Using Precedex and Other Sedatives

NCT01169467 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2015-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effects of using dexmedetomidine (Precedex) in addition to the current standard-of-care for sedation.

Conditions

  • Endotracheal Intubation
  • Continuous IV Sedation
  • ICP Monitoring

Interventions

DRUG

Standard-of-Care plus Dexmedetomidine

Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment

OTHER

Standard-of-Care

Subjects who are treated with the standard of care sedation regiment only.

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Keith Dombrowski, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01169467 on ClinicalTrials.gov